Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annu...(36 in both type 2 diabetes and obesityap...),Health

Date:10/25/2007

36 in both type 2 diabetes and obesity applications. The response by the scientific and medical attendees to both Genaera poster presentations was encouraging and supportive and we enthusiastically look forward to further exploring the potential of this unique and promising drug. Also important to note is that we are very encouraged by the initial Phase 2 MEDI-528 results to date as presented at the Chest Physicians Meeting in Chicago. MedImmune indicates that these results offer positive reasons to continue with the remainder of their Phase 2 program."

Genaera notes that both poster presentations are now available on the Company website at http://www.genaera.com.

About Trodusquemine

Trodusquemine (MSI-1436) is the first drug candidate that acts both centrally and peripherally to selectively inhibit the established and validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B). The dual locations of MSI-1436 action make the drug a promising candidate for both type 2 diabetes and obesity. By inhibiting PTP-1B, trodusquemine has been shown to decrease appetite and normalize blood sugar as PTB-1B is central to both the insulin and leptin pathways. Based on this unique mechanism of action, trodusquemine has the potential to bridge the treatment for two of the most serious metabolic diseases, type 2 diabetes and obesity. In addition, trodusquemine has overcome selectivity concerns that other compounds that target PTP-1B have failed to overcome. Preclinical studies demonstrate that trodusquemine is a potent, highly selective and reversible inhibitor of PTP- 1B. In vitro kinetics demonstrate that trodusquemine is a reversible, allosteric, noncompetitive inhibitor of PTP-1B, binding to a site different from the catalytic site of PTP-1B. Data also demonstrate that trodusquemine can produce consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment
'/>"/>

SOURCE Genaera Corporation Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
10. XTL Provides Update on Phase I Clinical Trial of XTL-2125
11. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age